Two Onc Docs

Explore groundbreaking advancements in genitourinary oncology presented at the 2025 ASCO Annual Meeting. Discover insights on prostate cancer, including the latest on PSA response prognostication and the Amplitude trial. Learn about innovations in treating muscle-invasive bladder cancer, especially findings from the NIAGARA trial. Key updates on renal cell carcinoma reveal adjuvant pembrolizumab's survival benefits. The discussion also highlights the role of ctDNA in personalizing treatment and improving patient outcomes across various cancers.

Get ready for groundbreaking insights from the upcoming ASCO Annual Meeting! Discover cutting-edge research on bladder cancer, including innovative therapies and the role of ctDNA. Explore major advancements in renal cell carcinoma, featuring pivotal trials and new treatment strategies. Plus, dive into the latest in prostate cancer, where prognostic values and the impact of new drugs are making waves. Don’t miss the exciting developments in genitourinary cancers and unique educational sessions that will shape the future of oncology.

Dive into the complexities of hepatocellular carcinoma, emphasizing the critical role of liver function evaluation. Discover the significance of the Child-Pugh score in staging HCC, and recent advancements in treatment options like immunotherapy and new medications. Learn about innovative strategies to enhance survival rates and tailor therapies based on individual patient needs. The discussion reveals insights on treatment-related risks, ensuring a well-rounded understanding for effective management of this challenging condition.

Jeff Auletta, a pioneer in stem cell transplantation and infectious diseases, shares insights from his role at the National Marrow Donor Program. He explores the intricacies of conditioning regimens, including myeloblative and non-myeloablative methods. The conversation delves into the complexities of graft-versus-host disease, highlighting treatment strategies and challenges. Auletta also emphasizes the importance of managing transfusion complications and shares his emotional connections with pediatric patients, underscoring the vital role of stem cell research.

Joining the discussion is Dr. Jeff Auletta, a leading voice in blood and marrow transplantation. He shares insights on hematopoietic stem cell transplants, clarifying the various types and the donor matching process. The conversation dives into the risks and benefits of autologous versus allogeneic transplants, highlighting critical disparities in donor availability across ethnic groups. Dr. Auletta also emphasizes the need for systemic changes to address socio-economic barriers and ensure equitable access to transplant services for all communities.

A deep dive into non-seminoma testicular cancer reveals vital tumor markers like AFP, LDH, and HCG essential for diagnosis. The management strategies for both early-stage and advanced disease are explored, emphasizing personalized treatment plans. Key discussions include the importance of monitoring long-term side effects and fertility issues. The surgical approach to managing residual disease is highlighted, along with upcoming trial results shedding light on chemotherapy options for relapsed cases. This enlightening conversation underscores advances in treatment and patient care.

Dive into the world of seminoma, a form of testicular cancer, and discover crucial management strategies and risk factors. Learn about the importance of early symptom recognition, especially in young patients. Explore the diagnosing process with ultrasounds and the significance of tumor markers in monitoring. Unpack various chemotherapy regimens and their tailored approaches based on disease staging. Finally, navigate the complex treatment protocols, focusing on the distinct management of seminoma versus non-seminoma.

Delve into the complexities of Chronic Lymphocytic Leukemia with updates on personalized treatment strategies and the latest therapies like CAR-T and non-covalent BTK inhibitors. Unpack the diagnostic criteria, staging systems, and essential prognostic factors, including immunoglobulin mutations. Discover the balance between treatment and observation for improved outcomes, while also addressing treatment toxicities and cardiovascular risks. Gain insights into managing initial and refractory disease, ensuring effective patient care.

Dr. Charles Ryan, a leading GU oncologist from MSK in NYC, returns to share vital updates on metastatic prostate cancer. He discusses the differences between castrate-sensitive and castrate-resistant prostate cancer, crucial for treatment strategies. Advancements like PARP inhibitors and immunotherapy take center stage, alongside the necessity for genomic testing. Ryan emphasizes learning from clinical trials, whether outcomes are positive or negative. He also inspires future oncologists by showcasing the stunning progress in cancer treatment, blending research with heartfelt encouragement.

Dr. Charles Ryan, a leading GU oncologist at Memorial Sloan Kettering, discusses the latest in localized prostate cancer. He highlights the declining PSA screening rates and their impact on diagnosis. The conversation touches on key risk factors like age and genetics, and advances in diagnostics, including genomic data. Hormone therapy's role and patient management strategies are also examined. Additionally, he addresses biochemical recurrence post-treatment and the promising results of recent trials like EMBARK, emphasizing the evolving landscape of prostate cancer care.